Basic Stats
| LEI | 529900XBHFGMNTU70154 |
| CIK | 1178253 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SCYNEXIS, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-3636 |
|
| July 1, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-363 |
|
| April 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commis |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| March 12, 2025 |
Exhibit 19.1 SCYNEXIS, inc. INSIDER TRADING AND TRADING WINDOW POLICY (Revised December 31, 2018) I. Introduction This policy determines acceptable transactions in the securities of SCYNEXIS, Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publ |
|
| February 14, 2025 |
EX-99 2 d11606582ex99-a.htm Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. 6 dated February 14, 2025 relating to the Common Stock, par value $0.001 per share, of Scynexis, Inc. shall be filed on behalf of the undersigned. AVIDITY PARTNERS MANAGEMENT LP By Avidity Partners Management (GP) LLC, its general partner By: /s/ Michael Gregory Title: Managing M |
|
| January 8, 2025 |
EXHIBIT “3” POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints J. |
|
| January 8, 2025 |
AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934: 1. |
|
| January 8, 2025 |
ITEM 3 CLASSIFICATION OF REPORTING PERSONS Identity and Classification of Each Reporting Person EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS Identity and Classification of Each Reporting Person IDENTITY CLASSIFICATION UNDER ITEM 3 Federated Hermes Adviser Series (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U. |
|
| January 8, 2025 |
EXHIBIT “3” POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints J. |
|
| November 14, 2024 |
SCYX / SCYNEXIS, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1153047813g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Scynexis, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 6, 2024 |
Exhibit 1.1 Execution Version SCYNEXIS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement November 6, 2024 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: SCYNEXIS, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as follows: 1. Issuance and Sale of Shar |
|
| November 6, 2024 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275520 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 27, 2023) Up to $50,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to the shares of our common stock, par value $0.001 per share, offered by this prospectus supple |
|
| November 6, 2024 |
SCYX / SCYNEXIS, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 scynexisamend13.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292200 (CUSIP Number) October 31, 2024 (Date of Event Which |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001 |
|
| November 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 7, 2024 |
SCYX / SCYNEXIS, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 scynexisamend12.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292200 (CUSIP Number) September 30, 2024 (Date of Event Whi |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 10, 2024 |
A dynamic force in the fight against infectious disease September 2024 A dynamic force in the fight against infectious disease September 2024 Forward-Looking Statement Certain statements regarding SCYNEXIS, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. ( |
|
| June 20, 2024 |
Exhibit 99.2 SCYNEXIS, Inc. Stock Option Grant Notice (2024 Equity Incentive Plan) SCYNEXIS, Inc. (the “Company”) has granted to you (the “Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the SCYNEXIS, Inc. 2024 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set forth in this Stock Option Gr |
|
| June 20, 2024 |
Exhibit 99.3 SCYNEXIS, Inc. RSU Award Grant Notice (2024 Equity Incentive Plan) SCYNEXIS, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units (the “RSUs”) specified and on the terms set forth below in consideration of your services (the “RSU Award”). The RSU Award is subject to all of the terms and conditions set forth in this RSU Award Grant Notice (th |
|
| June 20, 2024 |
SCYNEXIS, Inc. 2024 Equity Incentive Plan. Exhibit 99.1 SCYNEXIS, INC. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 12, 2024 APPROVED BY THE STOCKHOLDERS: June 19, 2024 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 6 6. ADJUSTMENTS UPON CHANGES IN COMMON STO |
|
| June 20, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 SCYNEXIS, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 457(c) and 457(h) 6,150,000 $ 2.02 $ 12,423,000 0.0001476 $ 1,83 |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 20, 2024 As filed with the Securities and Exchange Commission on June 20, 2024 Registration No. |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| May 8, 2024 |
Employment Agreement, dated November 15, 2017, between SCYNEXIS, Inc. and Scott Sukenick Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT ("Agreement''), effective as of November 15, 2017 (the "Effective Date''), is by and between SCYNEXIS, Inc., a Delaware corporation ("Employer" or "Company' and Scott Sukenick ("Employee''). RECITALS: WHEREAS, Employer considers the availability of Employee's services to be important to the management and conduct of Employer's business an |
|
| May 8, 2024 |
Non-Employee Director Compensation Policy, as amended. Exhibit 10.2 SCYNEXIS Non-Employee Director Compensation Policy Revised April 2024 Our non-employee directors are compensated in accordance with the following policy: Each non-employee director receives an annual base cash retainer of $45,000 for such service, to be paid quarterly. In addition, the chairman of the Board receives an additional annual base cash retainer of $35,000, to be paid quarte |
|
| April 25, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| March 28, 2024 |
Exhibit 10.41 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. BINDING MEMORANDUM OF UNDERSTANDING FOR AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT AND TRANSITIONAL MANUFACTURING AND SUPPLY AGREEMENT This Binding Memorandum of Understanding for A |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2024 SCYNEXIS, Inc. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| March 28, 2024 |
Non-Employee Director Compensation Policy Exhibit 10.21 SCYNEXIS Non-Employee Director Compensation Policy Revised December 2023; Effective January 1, 2024 Our non-employee directors are compensated in accordance with the following policy: Each non-employee director receives an annual base cash retainer of $45,000 for such service, to be paid quarterly. In addition, the chairman of the Board receives an additional annual base cash retaine |
|
| March 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 SCYNEXIS, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 457(h) 1,916,962 $ 1.43 $ 2,741,256 0.0001476 $ 404.61 Equity Co |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97.1 SCYNEXIS, INC. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of SCYNEXIS, Inc., a Delaware corporation (the “Company”), and the Board have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (thi |
|
| March 28, 2024 |
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update Exhibit 99.1 SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update • SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 • Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyse |
|
| February 13, 2024 |
SCYX / SCYNEXIS, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1098044613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Scynexis, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 13, 2024 |
SCYX / SCYNEXIS, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 scyx13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Scynexis, Inc. (Name of Issuer) Common Stock, par value $0.001per share (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 13, 2024 |
SCYX / SCYNEXIS, Inc. / CAXTON CORP Passive Investment SC 13G/A 1 d1096535913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SCYNEXIS, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| January 18, 2024 |
SCYX / SCYNEXIS, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 scyx1577-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2023 (Date of Event Which |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2024 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 5, 2024 |
A dynamic force in the fight against infectious disease January 2024 A dynamic force in the fight against infectious disease January 2024 Forward-Looking Statement Certain statements regarding SCYNEXIS, Inc. |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 29, 2023 |
SCYX / Scynexis Inc / KINGDON CAPITAL MANAGEMENT, L.L.C. Passive Investment SC 13G/A 1 d1088830213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCYNEXIS, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) November 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 28, 2023 |
32,516,267 Shares Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-275513 PROSPECTUS 32,516,267 Shares Common Stock This prospectus relates to the offer and sale by us of 32,516,267 shares of our common stock, par value $0.001 per share, that are issuable upon the exercise of warrants, of which (i) warrants to purchase 6,800,000 shares of our common stock at an exercise price of $8.2 |
|
| November 28, 2023 |
$200,000,000 Common Stock Preferred Stock Debt Securities 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-275520 PROSPECTUS $200,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may offer and sell up to an aggregate amount of $200,000,000 any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or preferred stoc |
|
| November 21, 2023 |
SCYNEXIS, INC. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 SCYNEXIS, INC. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 November 21, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Cindy Polynice RE: SCYNEXIS, Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275520 Acceleration Request Requested Date: November 27, |
|
| November 21, 2023 |
SCYNEXIS, INC. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 SCYNEXIS, INC. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 November 21, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Cindy Polynice RE: SCYNEXIS, Inc. Registration Statement on Form S-3 Filed November 13, 2023 File No. 333-275513 Acceleration Request Requested Date: November 27, |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 13, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) SCYNEXIS, Inc. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, I |
|
| November 13, 2023 |
[*] = Certain information in this document has been excluded as such information is not material and is the type of information that the Company treats as private or confidential. |
|
| November 13, 2023 |
[*] = Certain information in this document has been excluded as such information is not material and is the type of information that the Company treats as private or confidential. |
|
| November 13, 2023 |
[*] = Certain information in this document has been excluded as such information is not material and is the type of information that the Company treats as private or confidential. |
|
| November 13, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate EX-4.7 Exhibit 4.7 SCYNEXIS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF SCYNEXIS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between, SCYNEXIS, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the laws of [•] |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 13, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) SCYNEXIS, Inc. |
|
| November 13, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate EX-4.8 Exhibit 4.8 SCYNEXIS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF SCYNEXIS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SCYNEXIS, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the laws |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 14, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. May 25, 2023 Scynexis, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302 Attn: Legal Department With a copy to: Cooley LLP 101 California Street, 5th Floor San Francisco, California 94114 Attn: Maricel Mojares-Moore Re: Payoff of |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. ( |
|
| July 18, 2023 |
Exhibit 99.1 SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan Adopted by the Board of Directors: February 11, 2014 Approved by the Stockholders: February 25, 2014 Adjusted for Reverse Stock Split: July 17, 2020 Amended by the Board of Directors: April 14, 2023 Approved by the Stockholders: June 14, 2023 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company a |
|
| July 18, 2023 |
As filed with the Securities and Exchange Commission on July 18, 2023 Registration No. |
|
| July 18, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 SCYNEXIS, Inc. Table 1: Newly Registered Securities Calculation of Filing Fee Table Form S-8 SCYNEXIS, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Co |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 SCYNEXIS, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36365 56-2181648 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 9, 2023 |
SCYX / Scynexis Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Scynexis, Inc. (Name of Issuer) Common Stock, par value $0.001per share (Title of Class of Securities) 811292200 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| May 10, 2023 |
Separation Agreement, dated October 20, 2022, between SCYNEXIS, Inc. and Christine Coyne. Exhibit 10.3 October 20, 2022 Christine Rose Coyne Dear Christine: This letter sets forth the substance of the separation agreement (the “Agreement”) that SCYNEXIS, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be November 30, 2022 (the “Separation Date”). 2. Accrued Sala |
|
| May 10, 2023 |
Exhibit 10.2 First AMENDMENT AND CONSENT TO LOAN AND SECURITY AGREEMENT This First Amendment AND CONSENT to Loan and Security Agreement (this “Amendment”) is dated as of March 30, 2023 and is entered into by and among SCYNEXIS, INC., a Delaware corporation (“Borrower”), HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent (“Agent”), SILICON V |
|
| May 10, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN SCYNEXIS, INC. AND GlaxoSmithKline Intellectual Property (No. 3) Limited DATED AS OF March 30, 2023 Table of Contents Page Article 1 DEFI |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| May 1, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as pe |
|
| April 19, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| April 13, 2023 |
SCYX / Scynexis Inc / KINGDON CAPITAL MANAGEMENT, L.L.C. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2023 |
SCYX / Scynexis Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 4 Under the Securities Exchange Act of 1934 SCYNEXIS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 811292101 (CUSIP Number) March 22, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| March 31, 2023 |
Separation Agreement, dated October 20, 2022, between SCYNEXIS, Inc. and Marco Taglietti. Exhibit 10.38 October 20th, 2022 Dr. Marco Taglietti Dear Marco: This letter sets forth the substance of the separation agreement (the “Agreement”) that SCYNEXIS, Inc. (the “Company”) is offering to you. 1. Separation. Your last day of work with the Company and your employment termination date will be December 31, 2022 (the “Separation Date”). 2. Accrued Salary and Paid Time Off. By the date requi |
|
| March 31, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 SCYNEXIS, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 457(h) 1,901,960 $ 1.84 $ 3,499,606 0.0001102 $ 385.66 Equity Co |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. |
|
| March 31, 2023 |
Exhibit 10.39 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”), effective as of January 1, 2023 (the “Effective Date”), is by and between SCYNEXIS, Inc., a Delaware corporation (“Employer” or “Company”) and David Angulo Gonzalez, MD (“Employee”). RECITALS: WHEREAS, Employer considers the availability of Employee's services to be important to the management and conduct of Employer's bus |
|
| March 31, 2023 |
Exhibit 10.40 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT ("Agreement"), effective as of October 24, 2022 (the "Effective Date"), is by and between SCYNEXIS, Inc., a Delaware corporation ("Employer" or "Company") and Ivor Macleod ("Employee"). RECITALS: WHEREAS, Employer considers the availability of Employee's services to be important to the management and conduct of Employer's business and de |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 SCYNEXIS, Inc. |
|
| February 15, 2023 |
SCYX / SCYNEXIS Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 3 Under the Securities Exchange Act of 1934 SCYNEXIS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 811292101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 14, 2023 |
SCYX / SCYNEXIS Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
SCYX / SCYNEXIS Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-scyx123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCYNEXIS, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 1, 2023 |
SCYX / SCYNEXIS Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| November 10, 2022 |
S-8 1 forms-8-11112022.htm S-8 As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SCYNEXIS, Inc. (Exact name of Registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incorporation |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 SCYNEXIS, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 457(h) 400,000 $ 2.235 $ 894,000 0.0001102 $ 98.52 Total Offerin |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2022 SCYNEXIS, Inc. |
|
| November 9, 2022 |
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update • SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications. |
|
| November 9, 2022 |
Exhibit 10.2 Scynexis, Inc. Restricted Stock Unit Award Grant Notice 2015 Inducement Award Plan SCYNEXIS, Inc. (the ?Company?) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the ?Award?). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the ?Grant Notice?), in the Restrict |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, I |
|
| November 9, 2022 |
Exhibit 3.4 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SCYNEXIS, Inc. SCYNEXIS, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies that: First: The name of the Corporation is SCYNEXIS, Inc. The Corporation was originally incorporated under the name Scyrex, |
|
| November 9, 2022 |
Exhibit 10.1 SCYNEXIS, INC. 2015 INDUCEMENT AWARD PLAN ADOPTED: March 26, 2015 Amended: June 9, 2019 ADJUSTED FOR REVERSE STOCK SPLIT: July 17, 2020 FURTHER AMENDED: April 30, 2021 FURTHER AMENDED: OCTOBER 18, 2022 1. GENERAL. (a) Eligible Award Recipients. The persons eligible to receive Stock Awards are Eligible Employees as of the date of grant. (b) Available Awards. The Plan provides for the g |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2022 SCYNEXIS, Inc. |
|
| September 30, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 28, 2022 SCYNEXIS, Inc. |
|
| August 19, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2022 SCYNEXIS, Inc. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. ( |
|
| August 15, 2022 |
Non-Employee Director Compensation Policy. Exhibit 10.1 SCYNEXIS Non-Employee Director Compensation Policy Revised June 2022 Our non-employee directors are compensated in accordance with the following policy: Each non-employee director receives an annual base cash retainer of $40,000 for such service, to be paid quarterly. In addition, the chairman of the Board receives an additional annual base cash retainer of $35,000, to be paid quarter |
|
| August 15, 2022 |
SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? BREXAFEMME? (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1. |
|
| August 8, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as p |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 SCYNEXIS, Inc. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2022 SCYNEXIS, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| May 12, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ????Filed by a party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Onl |
|
| May 12, 2022 |
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update ? BREXAFEMME? (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022. Expansion of the labeling to include prevention of recurrent VVC is anticipated by end of 2022. ? As o |
|
| May 12, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT ("Agreement"), effective as of May 10, 2021 (the "Effective Date"), is by and between SCYNEXIS, Inc., a Delaware corporation ("Employer" or "Company") and Christine Coyne ("Employee"). RECITALS: WHEREAS, Employer considers the availability of Employee's services to be important to the management and conduct of Employer's business and desi |
|
| May 2, 2022 |
Non-Employee Director Compensation Policy Exhibit 10.36 SCYNEXIS Non-Employee Director Compensation Policy Revised January 2022 Our non-employee directors are compensated in accordance with the following policy: Each non-employee director receives an annual base cash retainer of $40,000 for such service, to be paid quarterly. In addition, the chairman of the Board receives an additional annual base cash retainer of $35,000, to be paid qua |
|
| May 2, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ????Filed by a party other than the Registrant ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| April 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 22, 2022 SCYNEXIS, Inc. |
|
| April 22, 2022 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT SCYNEXIS, INC. Warrant Shares: Issue Date: , 2022 Initial Exercise Date: , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) of SCYNEXIS, Inc., a Delaware corporation (the ?Company?), certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter |
|
| April 22, 2022 |
EX-1.1 2 scyx-ex119.htm EX-1.1 Exhibit 1.1 3,333,333 Shares of Common Stock ($0.001 Par Value) Pre-Funded Warrants to Purchase Up to 11,666,667 Shares of Common Stock Warrants to Purchase Up to 15,000,000 Shares of Common Stock SCYNEXIS, Inc. Common Stock EQUITY UNDERWRITING AGREEMENT April 22, 2022 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attach |
|
| April 22, 2022 |
Exhibit 4.2 PURSUANT TO THE TERMS OF SECTION 1 OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT SCYNEXIS, INC. IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL NU |
|
| April 22, 2022 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-251851 April 22, 2022 SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp?s Potency Against Severe Fungal Infections ? Data reinforce findings from previous analyses demonstrating oral ibrexafungerp?s potential to combat difficult-to-treat and refractory fungal in |
|
| April 22, 2022 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-251851 PROSPECTUS SUPPLEMENT (To Prospectus dated January 8, 2021) 3,333,333 Shares Common Stock Pre-Funded Warrants to Purchase 11,666,667 Shares of Common Stock Common Warrants to Purchase up to 15,000,000 Shares of Common Stock We are offering shares of our common stock. Each investor will also receive a warrant to purchase one share of o |
|
| April 21, 2022 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-251851 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in a |
|
| March 30, 2022 |
EX-FILING FEES 2 scyx-exfilingfees6.htm EX-FILING FEES Calculation of Filing Fee Table Form S-8 SCYNEXIS, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 457(h) 1,148,213 $ 4. |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 29, 2022 Registration No. |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2022 SCYNEXIS, Inc. |
|
| March 29, 2022 |
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update ? BREXAFEMME? (ibrexafungerp tablets), launched in August 2021, achieved net revenues of $1. |
|
| March 29, 2022 |
Exhibit 4.2 SCYNEXIS, INC. DESCRIPTION OF COMMON STOCK SCYNEXIS, Inc. (?we,? ?our,? ?us,? or the ?Company,?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description of our common stock does not purport to be complete and is subject in all respects to applicable Delaware law and to t |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2022 SCYNEXIS, Inc. |
|
| February 14, 2022 |
SCYX / SCYNEXIS Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2022 |
SCYX / SCYNEXIS Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCYNEXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 811292 200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2022 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2022 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2022 |
SCYX / SCYNEXIS Inc / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SCYNEXIS, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2022 |
SCYX / SCYNEXIS Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
SCYX / SCYNEXIS Inc / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
SCYX / SCYNEXIS Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 SCYNEXIS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 811292101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 8, 2022 |
Exhibit 10.1 2014 SCYNEXIS, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive plan SCYNEXIS, Inc. (the ?Company?) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the ?Award?). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the ?Grant Notice?), in the Res |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2022 SCYNEXIS, Inc. |
|
| December 10, 2021 |
SCYX / SCYNEXIS Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292101 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statem |
|
| November 12, 2021 |
SCYX / SCYNEXIS Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 SCYNEXIS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 811292101 (CUSIP Number) November 9, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 10, 2021 |
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update ? BREXAFEMME? (ibrexafungerp tablets) net sales of $0. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 SCYNEXIS, Inc. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEX |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2021 SCYNEXIS, Inc. |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2021 SCYNEXIS, Inc. |
|
| September 17, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-259300 5,271,015 Shares Common Stock This prospectus relates to the offer and sale by us of 5,271,015 shares of our common stock, par value $0.001 per share, that are issuable upon the exercise of warrants, of which (i) warrants to purchase 798,810 shares of our common stock at an exercise price of $20.00 per share were originally issued by us |
|
| September 17, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-259300 $16,798,087 of Common Stock Pursuant to this prospectus we are offering up to $16,798,087 aggregate amount of our common stock, par value $0.001 per share (the ?Purchase Shares?), to Aspire Capital Fund, LLC (?Aspire Capital?) under a Common Stock Purchase Agreement entered into on April 10, 2020 (?Purchase Agreement?). The Purchase Shar |
|
| September 13, 2021 |
SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, NJ 07302-6548 SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, NJ 07302-6548 Via Edgar September 10, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Laura Crotty Re: SCYNEXIS, Inc. Registration Statement on Form S-3 Filed September 3, 2021 File No. 333- 259300 Ladies and Gentlemen: The undersigned registrant hereby requests that |
|
| September 3, 2021 |
As filed with the Securities and Exchange Commission on September 3, 2021 As filed with the Securities and Exchange Commission on September 3, 2021 Registration No. |
|
| August 16, 2021 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?) dated as of May 13, 2021 (the ?Effective Date?), among (a) HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent (?Agent?), (b) SILICON VALLEY BANK, a California corporation, as a lender (?SVB?), (c) HERCULES CAPITAL, INC., a Maryland corporation (?Her |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, I |
|
| August 16, 2021 |
Exhibit 10.2 SCYNEXIS Non-Employee Director Compensation Policy Revised June 2021 Our non-employee directors are compensated in accordance with the following policy: Each non-employee director receives an annual base cash retainer of $40,000 for such service, to be paid quarterly. In addition, the chairman of the Board receives an additional annual base cash retainer of $30,000, to be paid quarter |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2021 SCYNEXIS, Inc. |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2021 SCYNEXIS, Inc. |
|
| June 10, 2021 |
SCYX / SCYNEXIS Inc / HIRSCHMAN ORIN - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SCYNEXIS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 811292101 (CUSIP Number) June 2, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed o Rule 13d-1(b |
|
| May 18, 2021 |
Exhibit 1.2 SCYNEXIS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement May 17, 2021 Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor New York, New York 10172 Ladies and Gentlemen: SCYNEXIS, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Ladenburg Thalmann & Co. Inc. (?Ladenburg?), as follows: 1.Issuance and Sale of |
|
| May 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2021 SCYNEXIS, Inc. |
|
| May 18, 2021 |
EX-1.1 2 scyx-ex116.htm EX-1.1 Exhibit 1.1 SCYNEXIS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement May 17, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: SCYNEXIS, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as follows: 1.Issuance and Sale of S |
|
| May 17, 2021 |
Exhibit 10.1 [*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) is the type of information that SCYNEXIS, Inc. treats as private or confidential. EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT This Exclusive License and Collaboration Agreement (this ?Agreement?) is made as of February 11, 2021 (the ?Effectiv |
|
| May 17, 2021 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-251851 PROSPECTUS SUPPLEMENT (To Prospectus dated January 8, 2021) $50,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or Cantor sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and a Controlled Equity OfferingSM Sales Agreement, or Ladenburg sales agreement, with Ladenburg Thalma |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, |
|
| May 17, 2021 |
Exhibit 10.2 [*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) is the type of information that SCYNEXIS, Inc. treats as private or confidential. MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (the ?Agreement?), effective as of February 4, 2021 (the ?Effective Date?), is by and between SCYNEXIS, I |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 SCYNEXIS, Inc. |
|
| May 10, 2021 |
Exhibit 99.1 SCYNEXIS, INC. 2015 INDUCEMENT AWARD PLAN ADOPTED: March 26, 2015 Amended: June 9, 2019 ADJUSTED FOR REVERSE STOCK SPLIT: July 17, 2020 FURTHER AMENDED: April 30, 2021 1. GENERAL. (a) Eligible Award Recipients. The persons eligible to receive Stock Awards are Eligible Employees as of the date of grant. (b) Available Awards. The Plan provides for the grant of the following Stock Awards |
|
| May 10, 2021 |
As filed with the Securities and Exchange Commission on May 10, 2021 Registration No. |
|
| April 26, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only ( |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 29, 2021 |
Exhibit 4.2 SCYNEXIS, INC. DESCRIPTION OF COMMON STOCK SCYNEXIS, Inc. (?we,? ?our,? ?us,? or the ?Company,?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description of our common stock does not purport to be complete and is subject in all respects to applicable Delaware law and to t |
|
| March 29, 2021 |
As filed with the Securities and Exchange Commission on March 29, 2021 Registration No. |
|
| March 29, 2021 |
Exhibit 10.30 FOURTH AMENDMENT TO TERMINATION AND LICENSE AGREEMENT THIS FOURTH AMENDMENT TO TERMINATION AND LICENSE AGREEMENT (the ?Fourth Amendment?) is made and entered into as of December 2, 2020 by and between Merck Sharp & Dohme Corp., a New Jersey corporation with a place of business at One Merck Drive, Whitehouse Station, NJ 08889 (?Merck?) and SCYNEXIS, Inc., a Delaware corporation with a |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| March 10, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292101 (CUSIP Number) February 28, 2021 (Date of Event Which Requires Filing of this Statem |
|
| February 23, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2021 SCYNEXIS, Inc. |
|
| February 17, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2021 SCYNEXIS, Inc. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCYNEXIS, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statem |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2) * Scynexis, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 811292200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 27, 2021 |
EX-99.1 2 d34407dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: January 27, 202 |
|
| January 27, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SCYNEXIS, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 811292 200 (CUSIP Number) December 21, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 6, 2021 |
SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 January 6, 2021 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Jeffrey Gabor RE: SCYNEXIS, Inc. Registration Statement on Form S-3 File No. 333-251851 Ladies and Gentlemen: SCYNEXIS, Inc. (the “Registrant”) hereb |
|
| December 31, 2020 |
As filed with the Securities and Exchange Commission on December 31, 2020 Registration No. |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SCYNEXIS, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292200 (CUSIP Number) December 17, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 18, 2020 |
EX-4.1 3 scyx-ex4146.htm EX-4.1 Exhibit 4.1 PURSUANT TO THE TERMS OF SECTION 1 OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT SCYNEXIS, INC. IN ADVANCE OF ACQUIRING THIS WARRANT |
|
| December 18, 2020 |
EX-1.1 2 scyx-ex1133.htm EX-1.1 Execution Version 8,340,000 Shares of Common Stock ($0.001 Par Value) Pre-Funded Warrants to Purchase Up to 5,260,000 Shares of Common Stock Series 1 Warrants to Purchase Up to 6,800,000 Shares of Common Stock Series 2 Warrants to Purchase up to 6,800,000 Shares of Common Stock SCYNEXIS, Inc. Common Stock EQUITY UNDERWRITING AGREEMENT December 17, 2020 Guggenheim Se |
|
| December 18, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2020 SCYNEXIS, Inc. |
|
| December 18, 2020 |
Form of Series 1 and Series 2 Warrant Exhibit 4.2 PURSUANT TO THE TERMS OF SECTION 1 OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT SCYNEXIS, INC. IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL NU |
|
| December 17, 2020 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-248751 PROSPECTUS SUPPLEMENT (To Prospectus dated October 1, 2020) 8,340,000 Shares Common Stock Pre-Funded Warrants to Purchase 5,260,000 Shares of Common Stock Common Warrants to Purchase up to 13,600,000 Shares of Common Stock We are offering shares of our common stock. Each investor will also receive a warrant to purchase 0.5 of a share |
|
| December 16, 2020 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-248751 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in a |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2020 SCYNEXIS, Inc. |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEX |
|
| October 2, 2020 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-248751 PROSPECTUS $50,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or Cantor sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and a Controlled Equity OfferingSM Sales Agreement, or Ladenburg sales agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg Thalmann, relating to |
|
| October 2, 2020 |
$200,000,000 Common Stock Preferred Stock Debt Securities As Filed Pursuant to Rule 424(b)(5) Registration No. 333-248751 $200,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may offer and sell up to an aggregate amount of $200,000,000 any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or preferred stock upon conversion of debt securitie |
|
| September 28, 2020 |
SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 September 28, 2020 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Abby Adams RE: SCYNEXIS, Inc. Registration Statement on Form S-3 File No. 333-248751 Ladies and Gentlemen: SCYNEXIS, Inc. (the “Registrant”) hereb |
|
| September 11, 2020 |
EX-1.3 3 scyx-ex137.htm EX-1.3 Exhibit 1.3 SCYNEXIS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement September 11, 2020 Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor New York, New York 10172 Ladies and Gentlemen: SCYNEXIS, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg” |
|
| September 11, 2020 |
EX-1.2 2 scyx-ex126.htm EX-1.2 Exhibit 1.2 SCYNEXIS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement September 11, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: SCYNEXIS, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as follows: 1.Issuance and Sal |
|
| September 11, 2020 |
As filed with the Securities and Exchange Commission on September 11, 2020 Registration No. |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, I |
|
| August 10, 2020 |
Exhibit 10.4 SCYNEXIS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 11, 2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 Adjusted for Reverse Stock Split: July 17, 2020 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of C |
|
| August 10, 2020 |
SCYNEXIS, Inc. Amended and Restated Stock Plan Exhibit 10.1 SCYNEXIS, INC. STOCK OPTION PLAN, AS AMENDED AND RESTATED RE-ADOPTED BY THE BOARD OF DIRECTORS: June 18, 2014 APPROVED BY THE STOCKHOLDERS: September 11, 2014 ADJSTED FOR REVERSE STOCK SPLIT: July 17, 2020 1. Purpose. The SCYNEXIS, Inc. Stock Option Plan, as amended and restated (the “Plan”) is established to create an additional incentive for key employees, directors and consultants |
|
| August 10, 2020 |
Exhibit 10.3 SCYNEXIS, INC. 2014 EQUITY INCENTIVE PLAN, AS AMENDED ADOPTED BY THE BOARD OF DIRECTORS: February 11, 2014 APPROVED BY THE STOCKHOLDERS: February 25, 2014 AS AMENDED BY THE BOARD OF DIRECTORS: June 18, 2014 AS APPROVED BY THE STOCKHOLDERS: September 11, 2014 AS AMENDED BY THE BOARD OF DIRECTORS: March 26, 2015 AS APPROVED BY THE STOCKHOLDERS: , 2015 EFFECTIVE DATE: May 2, 2014 Adjuste |
|
| August 10, 2020 |
SCYNEXIS, Inc. Amended and Restated 2015 Inducement Plan Exhibit 10.5 SCYNEXIS, INC. 2015 INDUCEMENT AWARD PLAN ADOPTED: March 26, 2015 Amended: June 9, 2019 ADJUSTED FOR REVERSE STOCK SPLIT: July 17, 2020 1. GENERAL. (a) Eligible Award Recipients. The persons eligible to receive Stock Awards are Eligible Employees as of the date of grant. (b) Available Awards. The Plan provides for the grant of the following Stock Awards: (i) Options, (ii) Stock Apprec |
|
| August 10, 2020 |
SCYNEXIS, Inc. Amended and Restated 2009 Stock Option Plan Exhibit 10.2 SCYNEXIS, INC. 2009 STOCK OPTION PLAN ADJUSTED FOR RESERVE STOCK SPLIT: July 17, 2020 1. Purpose The purpose of this 2009 Stock Option Plan (the “Plan”) of SCYNEXIS, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contrib |
|
| August 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2020 SCYNEXIS, Inc. |
|
| July 16, 2020 |
EX-3.1 2 scyx-ex316.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SCYNEXIS, Inc. SCYNEXIS, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies that: First: The name of the Corporation is SCYNEXIS, Inc. The Corporation was originally inco |
|
| July 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2020 SCYNEXIS, Inc. |
|
| July 7, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2020 SCYNEXIS, Inc. |
|
| May 29, 2020 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| May 15, 2020 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, |
|
| May 11, 2020 |
19,386,000 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237952 Prospectus 19,386,000 Shares Common Stock This prospectus relates to the sale or other disposition from time to time of up to 19,386,000 shares of our common stock issuable pursuant to convertible senior notes that may convert into up to an aggregate of 19,386,000 shares of our common stock, to be sold by the selling stockholder named in |
|
| May 7, 2020 |
SCYNEXIS, Inc. 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 May 7, 2020 Via Email and Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Alan Campbell RE: SCYNEXIS, Inc. Registration Statement on Form S-3 File No. 333-237952 Ladies and Gentlemen: SCYNEXIS, Inc. (the “Registrant”) hereby re |
|
| May 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2020 SCYNEXIS, Inc. |
|
| May 1, 2020 |
As filed with the Securities and Exchange Commission on May 1, 2020 Registration No. |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| April 28, 2020 |
Non-Employee Director Compensation Arrangements EX-10.24 2 scyx-ex1024104.htm EX-10.24 Exhibit 10.24 Our non-employee directors are compensated in accordance with the following policy: Each non-employee director receives an annual base cash retainer of $35,000 for such service, to be paid quarterly. In addition, the chairman of the Board receives an additional annual base cash retainer of $28,000, to be paid quarterly. In addition, each member |
|
| April 24, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2020 SCYNEXIS, Inc. |
|
| April 21, 2020 |
EX-99.1 2 d895609dex991.htm EX-99.1 Exhibit 99.1 SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) Published: Apr 21, 2020 • Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints • Ib |
|
| April 21, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2020 SCYNEXIS, Inc. |
|
| April 13, 2020 |
EX-4.1 2 scyx-ex418.htm EX-4.1 Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 10, 2020, by and between SCYNEXIS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined he |
|
| April 13, 2020 |
EX-10.1 4 scyx-ex1017.htm EX-10.1 Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of April 10, 2020 by and between SCYNEXIS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 |
|
| April 13, 2020 |
$20,000,000 of Common Stock plus 709,103 Commitment Shares Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-227167 PROSPECTUS SUPPLEMENT (To Prospectus dated September 14, 2018) $20,000,000 of Common Stock plus 709,103 Commitment Shares Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to $20.0 million aggregate amount plus 709,103 shares of our common stock, par value $0.001 |
|
| April 13, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2020 SCYNEXIS, Inc. |
|
| April 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36365 56-2181648 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 9, 2020 |
EX-10.1 2 scyx-ex10114.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION SCYNEXIS, INC., as Issuer, AND Puissance Life Science Opportunities Fund VI, as the Investor Senior Convertible Note Purchase Agreement Dated as of April 9, 2020 6.0% Convertible Senior Notes due 2026 ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Acts of Holder; Record D |
|
| March 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. |
|
| March 11, 2020 |
SCYX / SCYNEXIS, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on March 11, 2020 Registration No. |
|
| March 11, 2020 |
EX-4.2 2 scyx-ex42253.htm EX-4.2 Exhibit 4.2 SCYNEXIS, INC. DESCRIPTION OF COMMON STOCK SCYNEXIS, Inc. (“we,” “our,” “us,” or the “Company,”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description of our common stock does not purport to be complete and is subject in all respects to |
|
| February 14, 2020 |
SCYX / SCYNEXIS, Inc. / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
SCYX / SCYNEXIS, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) SCYNEXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 811292101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2020 |
SCYX / SCYNEXIS, Inc. / Puissance Life Science Opportunities Fund Vi Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1) * Scynexis, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 811292101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| December 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SCYNEXIS, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 811292101 (CUSIP Number) December 12, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| December 20, 2019 |
SCYX / SCYNEXIS, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36365 56-2181648 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 12, 2019 |
EX-4.1 3 d839015dex41.htm EX-4.1 Exhibit 4.1 SERIES 1 COMMON STOCK PURCHASE WARRANT SCYNEXIS, INC. Warrant Shares: Issue Date: December 12, 2019 Initial Exercise Date: , 2019 THIS SERIES 1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) of SCYNEXIS, Inc., a Delaware corporation (the “Company”), certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject |
|
| December 12, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36365 56-2181648 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 12, 2019 |
EX-1.1 Exhibit 1.1 Execution Version 38,888,889 Shares of Common Stock ($0.001 Par Value) Warrants to Purchase up to 38,888,889 Shares of Common Stock SCYNEXIS, Inc. Common Stock UNDERWRITING AGREEMENT December 10, 2019 H.C. Wainwright & Co., LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 |
|
| December 11, 2019 |
38,888,889 Shares Common Stock Warrants to Purchase up to 38,888,889 Shares of Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-227167 PROSPECTUS SUPPLEMENT (To Prospectus dated September 14, 2018) 38,888,889 Shares Common Stock Warrants to Purchase up to 38,888,889 Shares of Common Stock We are offering shares of our common stock. Each investor will also receive a warrant to purchase one share of our common stock at an exercise price of $1.10 |
|
| December 9, 2019 |
Common Stock Warrants to Purchase up to Shares of Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-227167 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. PROSPECTUS SUPPLEMENT (Subject to Completio |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEX |
|
| August 7, 2019 |
SCYX / SCYNEXIS, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on August 7, 2019 Registration No. |
|
| August 7, 2019 |
EX-3.2 2 scyx-ex3242.htm EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SCYNEXIS, Inc. SCYNEXIS, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies that: First: The name of the Corporation is SCYNEXIS, Inc. The Corporation was originally inc |
|
| August 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, I |
|
| August 7, 2019 |
Exhibit 10.1 SCYNEXIS, INC. 2015 INDUCEMENT AWARD PLAN ADOPTED: March 26, 2015 Amended: June 9, 2019 1. GENERAL. (a) Eligible Award Recipients. The persons eligible to receive Stock Awards are Eligible Employees as of the date of grant. (b) Available Awards. The Plan provides for the grant of the following Stock Awards: (i) Options, (ii) Stock Appreciation Rights (iii) Restricted Stock Awards, (iv |
